In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer
A total of 248 Gram-positive isolates from cancer patients were tested for in-vitro susceptibility to tedizolid and 3 comparator agents using CLSI broth microdilution methodology. Tedizolid inhibited 97% of isolates at ≤0.5μg/ml. It was active against all Gram-positive species and consistently had 8 fold lower MICs than linezolid, although based on % susceptibility using CLSI breakpoints, most isolates were also susceptible to the comparators. Tedizolid was active against MRSA isolates with vancomycin MICs of ≥ 1.0μg/ml.
Source: Diagnostic Microbiology and Infectious Disease - Category: Microbiology Authors: Kenneth V. IRolston, Ruth Reitzel, Nylev Vargas-Cruz, Samuel A. Shelburne, Issam I. Raad, Randall A. Prince Tags: Note Source Type: research
More News: Cancer | Cancer & Oncology | Infectious Diseases | Linezolid | Microbiology | MRSA | Superbugs | Zyvox